CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 115 enrolled
Drug / intervention
amlodipine/valsartandrug
Likely dose
amlodipine/valsartan 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02062645
NCT02062645Phase 4Completed
CompareCT.gov

A Single-Arm Open-Label Multicenter Phase IV Clinical Trial to Explore the Blood Pressure Lowering Effect of Exforge® (Amlodipine/Valsartan: AMLO/VAL) in Hypertensive Patients

Novartis Pharmaceuticals·interventional·Posted Feb 14, 2014·Updated Mar 28, 2017

In Brief

A Phase 4 clinical trial evaluating amlodipine/valsartan for Essential Hypertension. Completed, enrolled 115 participants across 8 sites.

Detailed Summary

The population that will be included in this study, will be regular Turkish hypertensive patients who are expected to consume sodium in high amounts. It is hypothesized that, in that population, amlodipine/valsartan will be effective at the same rate of blood pressure (BP) control rate as expected from literature.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesTurkey (Türkiye)
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 14, 2014
Enrollment StartFeb 1, 2014
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 12.4 years ago

Interventions

amlodipine/valsartandrug

Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg